Or R, Mehta J, Kapelushnik J, Aker M, Naparstek E, Nagler A, Cividalli G, Slavin S
Department of Bone Marrow Transplantation, Hadassah University Hospital, Jerusalem, Israel.
Bone Marrow Transplant. 1994 Jan;13(1):97-9.
Allogeneic BMT for severe aplastic anemia is associated with a significant rate of graft rejection, especially in patients who have been previously transfused. We report a child with aplastic anemia who rejected donor marrow twice despite adequate immunosuppression as part of the conditioning therapy but engrafted successfully following combined administration of three modalities of immunosuppression: antithymocyte globulin, total lymphoid irradiation and the monoclonal antibody Campath-1G. Restriction fragment length polymorphism studies > 1 year after BMT show full donor hematopoiesis with no evidence of autologous recovery.
严重再生障碍性贫血的异基因骨髓移植与较高的移植物排斥率相关,尤其是在既往接受过输血的患者中。我们报告了一名再生障碍性贫血患儿,尽管在预处理方案中进行了充分的免疫抑制,但仍两次排斥供体骨髓,不过在联合应用三种免疫抑制方式(抗胸腺细胞球蛋白、全身淋巴组织照射和单克隆抗体Campath-1G)后成功植入。骨髓移植1年多后的限制性片段长度多态性研究显示完全为供体造血,无自体恢复的迹象。